证券代码：600529 证券简称：山东药玻 公告编号：2025-060 山东省药用玻璃股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●委托理财受托方:中国工商银行股份有限公司 ●委托理财金额：人民币 28,000.00 万元 ●委托理财产品名称：区间累计型法人人民币结构性存款产品- 专户型 2025 年第 429 期 C 款 ●委托理财产品期限：92 天 ●履行的审议程序：公司于 2025 年 4 月 23 日召开了第十届董事 会第十七次会议和第十届监事会第十四次会议，并于 2025 年 5 月 16 日召开了公司 2024 年年度股东大会，审议通过了《关于使用闲置募 集资金购买理财产品的议案》，同意公司使用总额度不超过人民币八 亿元的暂时闲置募集资金进行购买安全性高、流动性好、期限不超过 12 个月（含）的保本型理财产品（包括但不限于协定性存款、结构 性存款、定期存款、通知存款、大额存单等），并在上述额度内滚动 使用，募集资金理财使用额度及授权的 ...

山东省药用玻璃股份有限公司 关于部分闲置募集资金购买理财产品到期赎回的公告 证券代码：600529 证券简称：山东药玻 公告编号：2025-059 2 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2025 年 4 月 23 日召开了第十届董事会第十七次会议和第 十届监事会第十四次会议，并于 2025 年 5 月 16 日召开了公司 2024 年年度股东大会，审议通过了《关于使用闲置募集资金购买理财产品 的议案》，同意公司使用总额度不超过人民币八亿元的暂时闲置募集 资金进行购买安全性高、流动性好、期限不超过 12 个月（含）的保 本型理财产品（包括但不限于协定性存款、结构性存款、定期存款、 通知存款、大额存单等），并在上述额度内滚动使用，募集资金理财 使用额度及授权的有效期为：自议案经公司 2024 年年度股东大会审 议通过之日起至 2025 年年度股东大会召开之日止。 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披 露的《山东省药用玻璃股份有限公司关于使用闲置募集资金购买理财 产品的公告 ...

Summary of Key Points Core Viewpoint - A total of 70 stocks in the A-share market experienced block trading today, with a total transaction value of 1.405 billion yuan, highlighting significant trading activity in specific stocks [1]. Group 1: Trading Activity - The top three stocks by transaction value were Huafeng Measurement Control (204 million yuan), YTO Express (73.74 million yuan), and Jiayuan Technology (69.22 million yuan) [1]. - Among the stocks traded, 3 were at par, 4 at a premium, and 63 at a discount, indicating a predominance of discounted trades [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were Yuntian Lifei-U (9.55%), Beijing Bank (2.25%), and Guangli Technology (1.65%) [1]. - The stocks with the highest discount rates were Yingtai Biotechnology (30.15%), Worth Buying (25.78%), and Shuyou Pingmin (24.29%) [1]. Group 3: Institutional Trading - The top institutional buy amounts were led by Huafeng Measurement Control (88.1285 million yuan), followed by Deep Sanda A (50.8776 million yuan) and Shandong Pharmaceutical Glass (45.0004 million yuan) [2]. - The leading institutional sell amount was for YTO Express (73.7455 million yuan), followed by Shandong Pharmaceutical Glass (45.0004 million yuan) and Wanda Information (7.21 million yuan) [2].

Core Viewpoint - The company is currently operating at near full capacity and has stable sales for its borosilicate glass products, with a positive outlook for export revenue growth in the coming years [2] Group 1: Production Capacity - The company's production lines are essentially at full capacity [2] - The pre-filled syringe project capacity will be gradually released based on equipment installation, debugging, and market conditions [2] Group 2: Sales and Revenue - Sales of borosilicate glass products are stable [2] - Export revenue is expected to grow year-on-year in the first three quarters of 2025 [2]

Core Viewpoint - The company's profit decline in the third quarter is primarily attributed to the weakening demand in the pharmaceutical packaging materials market, influenced by the deepening of domestic drug procurement policies and healthcare payment reforms [1] Company Summary - The company reported a profit decline in the first three quarters of the year [1] - The main reason for the profit decline is the impact of domestic drug procurement policies and healthcare payment reforms on market demand [1] Industry Summary - The pharmaceutical packaging materials market is experiencing reduced demand due to regulatory changes in the industry [1]

证券代码：600529 证券简称：山东药玻 公告编号：2025-058 山东省药用玻璃股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 11 月 17 日（星期一）09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 10 日（星期一）至 11 月 14 日（星 期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 sdyb@pharmglass.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 11 月 17 日（星期一）09:00-10:00 （二） 会议召开地点：上证路演中心 1 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 总经理：张军 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Views - The company reported a revenue of 3.401 billion, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 542 million, down 24.7% [3][4]. - The third quarter saw a revenue of 1.027 billion, a decline of 17.1%, with a net profit of 171 million, down 30.2% [3][4]. - Despite the demand pressure, the gross profit margin improved significantly, reaching 36.4% in Q3, an increase of 4.8 percentage points year-on-year, mainly due to the decline in raw material prices [8]. Summary by Sections Financial Performance - For the first three quarters, the company achieved a gross profit margin of 33.1%, up 1.0 percentage points year-on-year, despite a revenue decline attributed to weak pharmaceutical demand and pricing pressures from centralized procurement [8]. - The company’s net profit margin for the first three quarters was 16.0%, down 2.9 percentage points year-on-year [8]. - The cash collection ratio for the first three quarters was 117.0%, an increase of 15.7 percentage points year-on-year, indicating strong operational quality [8]. Market Conditions - The pharmaceutical packaging industry is currently facing significant demand pressure due to overall weak demand in the pharmaceutical sector and the impact of centralized procurement on pricing and rhythm [8]. - The penetration rate of borosilicate glass is expected to continue increasing in the medium term, with the company’s production capacity for primary water-resistant pharmaceutical glass bottles reaching expected targets [8]. Future Outlook - The company is projected to achieve net profits of 750 million and 850 million in 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 18.5 and 16.4 [8].

Core Viewpoint - The company reported a decline in revenue and net profit for the first three quarters of 2025, primarily due to weak industry demand and the impact of the national drug procurement policy [1][2]. Financial Performance - The company achieved a revenue of 3.401 billion yuan, a year-on-year decrease of 11.10% - The net profit attributable to shareholders was 542 million yuan, down 24.70% year-on-year - The non-recurring net profit attributable to shareholders was 516 million yuan, a decline of 25.13% year-on-year - The basic EPS was 0.82 yuan [1]. Demand and Market Conditions - The decline in revenue and profit was exacerbated compared to the first half of the year, with revenue down by an additional 2.9 percentage points and non-recurring net profit down by 3.12 percentage points [2]. - The implementation of the national drug procurement policy starting in April 2025 is expected to affect the demand for the company's borosilicate molded bottles until December 2027 [2]. Cost Structure and Profitability - The company's overall gross margin improved to 33.08%, an increase of 0.98 percentage points, attributed to a higher proportion of high-end products [3]. - The net profit margin decreased to 15.95%, down 2.89 percentage points, mainly due to increased management and R&D expense ratios, as well as inventory impairment losses [3]. - Management expense ratio rose to 5.71%, an increase of 1.88 percentage points, driven by higher employee compensation and depreciation [3]. - R&D expense ratio increased to 4.07%, up 1.05 percentage points, reflecting higher salaries for R&D staff [3]. - Inventory impairment losses amounted to 80.91 million yuan, a year-on-year increase of 168.25%, linked to declining product prices and rising inventory levels in a sluggish market [3]. Capacity Expansion and Strategic Developments - New production capacity is being established, enhancing the company's scale and competitive advantage, with a project for 4 billion borosilicate molded bottles nearing its production targets [4]. - The company is well-positioned to meet customer demand, and increased capacity may lead to lower unit costs in procurement and management [4]. - The change in controlling shareholder to China National Pharmaceutical Group is expected to provide new resources for development, leveraging the group's strengths in innovation and market access [4]. Profit Forecast - The company forecasts net profits attributable to shareholders of 743 million yuan, 885 million yuan, and 1.029 billion yuan for 2025, 2026, and 2027, respectively, with corresponding EPS of 1.12 yuan, 1.33 yuan, and 1.55 yuan [5]. - The projected PE ratios are 18.62, 15.64, and 13.44 for the same years, reflecting anticipated growth driven by increased production scale and the benefits of the new controlling shareholder [5].

Investment Rating - The report maintains a "Strong Buy" rating for Shandong Pharmaceutical Glass [2][6] Core Views - The company reported a revenue of 3.401 billion yuan for the first three quarters of 2025, a year-on-year decrease of 11.10%, and a net profit attributable to shareholders of 542 million yuan, down 24.70% year-on-year [3][4] - The decline in revenue and profit is attributed to weak industry demand, particularly due to the implementation of the 10th batch of national drug procurement starting in April 2025, which is expected to affect the demand for borosilicate molded bottles until December 2027 [4] - The company has improved its gross margin to 33.08%, an increase of 0.98 percentage points year-on-year, due to a higher proportion of high-end products [4] - The change in the controlling shareholder to China National Pharmaceutical Group is expected to provide new resources for the company's development, enhancing its market position and R&D capabilities [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a basic EPS of 0.82 yuan, with a net profit margin of 15.95%, down 2.89 percentage points year-on-year [3][4] - The management expense ratio increased to 5.71%, up 1.88 percentage points year-on-year, primarily due to rising employee compensation and depreciation [4] - The R&D expense ratio rose to 4.07%, an increase of 1.05 percentage points year-on-year, reflecting higher R&D personnel costs [4] Production Capacity and Market Position - The company is expanding its production capacity with a new project for 4 billion borosilicate molded bottles, which is expected to enhance its scale and competitive advantage [5] - The company’s production capacity is sufficient to meet customer demand, and once market demand recovers, it is anticipated to lead to significant performance elasticity [5] Profit Forecast - The forecast for net profit attributable to shareholders for 2025-2027 is 743 million, 885 million, and 1.029 billion yuan, respectively, with corresponding EPS of 1.12, 1.33, and 1.55 yuan [6]

Core Insights - The recombinant protein industry in China, despite its late start, has rapidly developed due to continuous support from national industrial policies, leading to significant breakthroughs in technology, production processes, and quality control [1][15] - The market for recombinant proteins is expected to grow steadily, driven by increased investment in innovative drug research, rising demand for precision medicine, and the expansion of downstream application scenarios [1][15] Industry Overview - Recombinant proteins are proteins obtained through genetic engineering and cell engineering, essential for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents [4] - The industry has experienced three stages: the initial stage (1970-1990), rapid development (1990-2000), and transformation and upgrading (2000-present) [8][9] Market Growth - The market size of China's recombinant protein industry is projected to grow from 5.1 billion yuan in 2015 to 27 billion yuan in 2024, with a compound annual growth rate (CAGR) of 20.34% [1][15] - The global recombinant protein market is expected to increase from $7 billion in 2015 to $18.5 billion in 2024, with a CAGR of 11.4% [13][14] Policy Support - The Chinese government has implemented various policies to encourage technological innovation and market expansion in the biopharmaceutical sector, including funding support for research and expedited drug approval processes [9][10] Industry Chain - The upstream of the recombinant protein industry includes raw materials and equipment, while the midstream consists of recombinant protein products, and the downstream includes customers such as research institutions and pharmaceutical companies [10] Competitive Landscape - The recombinant protein market is characterized by a diverse and dynamic competitive landscape, with major multinational pharmaceutical companies like Pfizer, Roche, and Novartis leading the market, while numerous small and medium-sized enterprises focus on innovative technologies [16][17] Development Trends - The industry is moving towards high-end products, focusing on complex structures and high-value proteins, with an emphasis on product activity, purity, and consistency [18] - Intelligent technologies, including AI and machine learning, are expected to enhance research and production processes, improving efficiency and product quality [19][20] - Chinese recombinant protein companies are increasingly participating in global competition, aiming to meet international standards and establish a strong global presence [21]